FDA Review Of Byetta Monotherapy Heads Into 2009
Amylin/Lilly say FDA is unlikely to complete a review of the diabetes application by the end of the year, as previously anticipated.
Amylin/Lilly say FDA is unlikely to complete a review of the diabetes application by the end of the year, as previously anticipated.